Cevimeline

Source: Wikipedia, the free encyclopedia.
Cevimeline
Clinical data
Trade namesEvoxac
AHFS/Drugs.comMonograph
MedlinePlusa608025
Pregnancy
category
  • C
Routes of
administration		By mouth (capsules)
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding<20%
Identifiers
  • (2R,2R)-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane]
JSmol)
  • O1[C@H](SC[C@@]12CN3CCC2CC3)C
  • InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 checkY
  • Key:WUTYZMFRCNBCHQ-PSASIEDQSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid

Sjögren's syndrome
.

Medical uses

Cevimeline is used in the treatment of

Sjögren's syndrome.[1] It increases the production of saliva.[2]

Side effects

Known side effects include

drowsiness, hot flashes, blurred vision, and difficulty sleeping.[3]

Contraindications include

angle closure glaucoma.[citation needed
]

Mechanism of action

Cevimeline is a cholinergic agonist.[2] It has a particular effect on M1 and M3 receptors.[2] By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

See also

  • Pilocarpine — a similar parasympathomimetic medication for dry mouth (xerostomia)
  • Bethanechol — a similar muscarinic parasympathomimetic with longer-lasting effect

References

  1. ^
    PMID 15234277
    .
  2. ^
    ISBN 978-0-323-47927-1
    .
  3. ^ "Cevimeline". MedicineNet. Retrieved 12 October 2007.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cevimeline&oldid=1181407590"